March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Pharmacokinetics of intravitreal bevacizumab (avastin) In vitrectomized eyes
Author Affiliations & Notes
  • Se Joon Woo
    Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Jeeyun Ahn
    Department of Ophthalmology, Seoul Metropolitan Boramae Medical Center, Seoul, Republic of Korea
  • Ji Hyun Park
    Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Sunyoung Park
    Chemical & Biomolecular Engineering, Sogang University, Seoul, Republic of Korea
  • Kyu Hyung Park
    Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Hyuncheol Kim
    Chemical & Biomolecular Engineering, Sogang University, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  Se Joon Woo, None; Jeeyun Ahn, None; Ji Hyun Park, None; Sunyoung Park, None; Kyu Hyung Park, None; Hyuncheol Kim, None
  • Footnotes
    Support  SNUBH research grant 11-2011-016
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 483. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Se Joon Woo, Jeeyun Ahn, Ji Hyun Park, Sunyoung Park, Kyu Hyung Park, Hyuncheol Kim; Pharmacokinetics of intravitreal bevacizumab (avastin) In vitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 2012;53(14):483.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To perform comparative analysis of pharmacokinetics of intravitreally injected bevacizumab in vitrectomized versus non-vitrectomized rabbit eyes.

Methods: : Among the 35 eyes of 35 rabbits included in the study, 25-gauge pars plana vitrectomy was performed in 18 right eyes (vitrectomized eyes), and the remaining 17 right eyes served as control (non-vitrectomized eyes). Both groups received 1.25mg/0.05mL bevacizumab intravitreally. Eyes were enucleated at 1 hour, 1, 2, 5, 14 and 30 days after the intravitreal injection and were immediately frozen at -70°C. Bevacizumab concentrations were determined after separation of frozen vitreous and aqueous humor compartments using direct enzyme-linked immunosorbent assay. Bevacizumab concentration-time data were fit by two-compartmental analysis to determine half-life.

Results: : The vitreous concentration of bevacizumab in both groups showed two phases of clearance which are the fast distribution phase and the slow elimination phase. Bevacizumab vitreous concentration in vitrectomized eye showed 94.7% (1 hour), 70.5% (1 day), 89.2% (2 days), 94.2% (5 days), 99.2% (14 days), and 79.1% (30 days) of that of non-vitrectomized eyes. The calculated overall half-lives of intravitreal bevacizumab were 6.99 days for vitrectomized eyes and 7.06 days for non-vitrectomized eyes (1.6 hours difference). The clearance of intravitreal bevacizumab in vitrectomized eyes was accelerated only in the first phase but not in the second phase.

Conclusions: : The increase of intravitreal bevacizumab clearance after vitrectomy is not substantial in rabbit eyes. This experimental data suggests that the therapeutic efficacy and duration of intravitreal bevacizumab in patients who previously underwent vitrectomy may be comparable to those without vitrectomy history.

Keywords: vitreous • age-related macular degeneration • vitreoretinal surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×